10-QPeriod: Q2 FY2010

Merck & Co., Inc. Quarterly Report for Q2 Ended Jun 30, 2010

Filed August 6, 2010For Securities:MRK

Summary

Merck & Co., Inc.'s second quarter 2010 results, as detailed in this 10-Q filing, demonstrate a company navigating the post-merger integration with Schering-Plough while facing ongoing patent expirations and product-specific challenges. Investors should note the impact of the Schering-Plough acquisition on reported revenues and expenses, which creates a complex comparison to prior periods. While the integration is progressing, it is essential to scrutinize the underlying performance of key product lines and the pipeline for future growth drivers. The company reported net sales growth primarily driven by the combined entity, but the underlying performance of specific segments, particularly in the pharmaceutical sector, requires careful consideration. Management's discussion highlights the continued importance of key products while also acknowledging the headwinds from generic competition. For investors, understanding Merck's strategic direction, its progress in realizing merger synergies, and its ability to innovate and bring new products to market will be crucial for assessing future profitability and shareholder value.

Financial Highlights

52 data points
Beta

Revenue

$11.35B

59.9% Gross Margin

Net Income

$752.00M

6.6% Net Margin

EPS (Diluted)

$0.24

Total Assets

$106.17B

Cash & Equivalents

$8.67B

Free Cash Flow

$3.33B

Financial Statements
Beta
Revenue$11.35B
Cost of Revenue$4.55B
Gross Profit$6.80B
R&D Expenses$2.18B
SG&A Expenses$3.17B
Interest Expense$185.00M
Net Income$752.00M
EPS (Basic)$0.24
EPS (Diluted)$0.24
Shares Outstanding (Basic)3.10B
Shares Outstanding (Diluted)3.13B

Key Highlights

  • 1Net sales increased significantly, largely due to the inclusion of Schering-Plough's results following the acquisition.
  • 2The company is actively managing the integration of Schering-Plough, focusing on realizing synergies and optimizing operations.
  • 3Patent expirations and generic competition continue to present headwinds for certain key pharmaceutical products.
  • 4Research and Development expenses remain a significant investment area, reflecting Merck's commitment to its pipeline.
  • 5The company reported a net loss, impacted by integration-related costs and other one-time charges associated with the acquisition.
  • 6Management commentary emphasizes the focus on executing the integration plan and maintaining commercial momentum for key brands.

Frequently Asked Questions

The acquisition of Schering-Plough significantly impacted Merck's financial performance by substantially increasing net sales due to the consolidation of Schering-Plough's revenues. However, it also led to increased expenses, including integration-related costs, and contributed to a net loss for the quarter. Comparisons to prior periods are less straightforward due to the combination of the two entities.

Merck is facing challenges including the ongoing integration of Schering-Plough, the impact of patent expirations on key pharmaceutical products leading to generic competition, and the need to continuously invest in its R&D pipeline to drive future growth.

Merck's strategy involves focusing on the commercial performance of its existing key products, leveraging the expanded portfolio from the Schering-Plough acquisition, and advancing its pipeline of new drugs and vaccines through significant R&D investment.

Merck reported a net loss in this quarter, which was significantly influenced by one-time integration-related expenses and other charges associated with the Schering-Plough acquisition. While sales have increased, these acquisition-related costs have impacted overall profitability.